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Abstract
Background: Acute kidney injury (AKI) is a common complication of critical illness and is associated with worse
outcomes. However, the influence of deterioration or improvement in renal function on clinical outcomes is unclear.
Using a large international database, we evaluated the prevalence and evolution of AKI over a 7-day period and its
effects on clinical outcomes in septic and non-septic critically ill patients worldwide.
Methods: From the 10,069 adult intensive care unit (ICU) patients in the Intensive Care Over Nations database, all those
with creatinine and urine output data were included in this substudy. Patients who developed sepsis during the ICU stay
(≥ 2 days after admission) were excluded. AKI was evaluated within 72 hours after admission and before discharge/death
up to day 7 according to the Acute Kidney Injury Network (AKIN) criteria.
Results: A total of 7970 patients were included, 59% of whom met AKIN criteria for AKI within the first 72 hours of the
ICU stay. Twenty-four per cent of patients had sepsis on admission, of whom 68% had AKI, compared to 57% of those
without sepsis on admission (p < 0.001). AKIN stage 3 (40% vs 24%, p < 0.001) and use of renal replacement therapy
(20% vs 5%, p < 0.0001) were more prevalent in patients with sepsis. Patients with sepsis and AKIN stage 3 were less
likely to improve to a lower stage during the 7-day follow-up period than non-septic patients with AKIN stage 3 (21% vs
32%, p < 0.0001). In-hospital mortality was related to severity of AKI and was reduced in patients in whom AKI improved
compared to those who remained stable or deteriorated, but remained higher than in patients without AKI, even if there
was apparent full recovery at day 7.
Conclusion: These findings illustrate the different kinetics of AKI in septic and non-septic ICU patients and emphasize
the important impact of AKI on mortality rates even when there is apparent full renal recovery at day 7.
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Background
Acute kidney injury (AKI) is a serious complication in
critically ill patients and is independently associated with
poorer outcomes, creating a large burden on both patients
and society [1, 2]. Approximately one out of five
non-severe sepsis patients develop AKI [3], increasing to
one to two-thirds of critically ill patients, and its prevalence
is increasing [4–9]. Approximately 50% of ICU patients
with AKI die and those patients surviving an episode of
AKI have an increased risk of developing chronic kidney
disease [10, 11]. Currently, there are no pharmacological
therapeutic options available to prevent or treat AKI and
management is limited to mitigating secondary haemo-
dynamic and toxic renal insults and providing supportive
measures, such as diuretics and renal replacement therapy
(RRT). AKI can be caused by a variety of factors [10], but
sepsis is the most important aetiology in the critically ill
[12]. Sepsis-associated AKI is distinct from non-sepsis
AKI, with differences in pathogenesis, patient characteris-
tics and clinical outcomes [12–14].
Global epidemiological data comparing the clinical
course and outcomes in septic and non-septic AKI are
sparse. Further, while the impact of development of
de-novo AKI on short and long-term outcomes is well
recognized, the influence of deterioration or improve-
ment in renal function on clinical outcomes after devel-
opment of AKI remains unclear, although these aspects
are of importance for clinical decision-making and
future research.
The objective of this study, therefore, was to provide
an overview of the prevalence and evolution of AKI and
its effect on clinical outcomes in critically ill adult pa-
tients worldwide to provide greater insight into the glo-
bal burden of this condition. Using a large global
registry of critically ill patient data collected during the
Intensive Care Over Nations (ICON) audit [15], we eval-
uated the effects of deterioration or improvement in
AKI severity on outcomes from septic and non-septic
AKI. We hypothesized that septic AKI would be associ-
ated with worse outcomes than non-septic AKI.
Methods
Study population
This was a substudy of the Intensive Care Over Nations
(ICON) audit, a multicentre, worldwide audit conducted
between 8 and 18 May 2012 to collect data on character-
istics, including organ dysfunction, infection and out-
comes, of adult critically ill patients worldwide. Full
details of the methodology have been published previ-
ously [15] and are provided in Additional file 1. Briefly,
participating centres were recruited by open invitation,
through national scientific societies, international meet-
ings and/or individual contacts. A list of participating cen-
tres is provided in Additional file 2. Participation was
voluntary with no financial reimbursement. In each insti-
tution, the study was approved by the institutional re-
search ethics committee in accordance with local ethical
regulations. Informed consent was not required due to the
observational and anonymous nature of the data collec-
tion. Participating centres prospectively collected data
from all adult patients (> 16 years) admitted to the ICU
during the study period, except those admitted for less
than 24 hours for routine postoperative surveillance.
Readmissions of previously included patients were not
considered. For the purposes of this substudy, only
patients with creatinine and urine output data were in-
cluded. Patients who developed sepsis during the ICU stay
(≥ 2 days after admission) were excluded because we
wanted to evaluate the impact of sepsis on ICU admission
on AKI outcomes.
Definitions
Sepsis was defined as the occurrence of at least one fail-
ing organ (Sepsis-related Organ Failure Assessment
(SOFA) score > 2 for respective organ system) combined
with the presence of infection, as defined according to
the International Sepsis Forum [16]. The presence of
AKI was evaluated using the Acute Kidney Injury
Network (AKIN) criteria [17]. AKI stages were deter-
mined according to the AKIN criteria, using the largest
increase between two values of serum creatinine ob-
tained maximally 48 hours apart within a maximum
period of 72 hours after ICU admission or the urine
output for the 24-hour period after ICU admission. As
urine output was only recorded per 24-hour period in
ICON, we adjusted the stage 1 and 2 urine output cri-
teria (Additional file 3: Table S1). The criterion (urine
output or serum creatinine) that led to the worst pos-
sible AKIN classification was used in each case. We
chose to use the AKIN criteria rather than the more
recent KDIGO criteria, because in the KDIGO definition
of AKI the creatinine criterion relies on the percentage
change over a period of 7 days (rather than 48 hours for
the AKIN criteria) and our aim was to demonstrate the
effect of deteriorating or resolving AKI during the first 7
days after ICU admission on outcome. To assess AKI
deterioration or improvement, the last serum creatinine
or urine output data available before discharge or death
up to day 7 were used to define the AKIN stage, again
using the criterion (urine output or serum creatinine)
that led to the worst possible AKIN classification in each
case. Patients who died were not penalized to a max-
imum stage. This AKIN stage was compared to the
initial stage, and patients were identified as having dete-
riorated, improved or remained the same. Complete
recovery was defined as improvement from AKIN stage
1, 2 or 3 to the No AKI category. The inotropic score
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was calculated to express the use of vasoactive/vasopres-
sor agents, as described elsewhere [18].
Patients with comorbid chronic renal failure (CRF), in-
dicated on the original ICON case report form by the
ICON investigator, were analysed as a separate subgroup.
Statistical analysis
All statistical analyses were conducted in the Department
of Intensive Care of Erasme Hospital. For the purpose of
this study, the world was divided into nine geographical
regions, and individual countries were classified into three
income groups in accordance with the gross national in-
come (GNI) per person [14]. Data are expressed as mean
and standard deviation (SD), median with interquartile
range (IQR, first–third quartiles) or numbers and percent-
ages. For continuous variables, normality assumption
checking was performed by inspection of residual and
normal plots and by using the Kolmogorov–Smirnov test.
Difference testing between groups was performed using
the generalized linear models procedure, Kruskal–Wallis
test, Student’s t test, Mann–Whitney test, χ2 test or
Fisher’s exact test, as appropriate.
To describe the prevalence of patients receiving RRT
up to day 7, data were imputed by the last observation
carried forward in the case of discharge or death. If a pa-
tient died before day 60, the ICU and hospital length of
stay (LOS) was each set to 60 days.
Data were censored at day 60. In addition, discharge
of a patient was considered a competing risk factor for
the occurrence of death. A competing risk regression
model [19] was used to estimate crude and adjusted haz-
ard ratios (HRs) and their 95% CIs for ICU and hospital
mortality according to the AKI stage or CRF group. To
determine the adjusted relative risk of in-ICU or
in-hospital death, we developed a multivariable compet-
ing risk proportional hazard regression model, stratified
according to the presence or not of sepsis. Other con-
founding variables considered included age, sex, Acute
Physiology and Chronic Health Evaluation (APACHE) II
score without age and renal components, type of admis-
sion, source of admission, reason for admission, the need
for mechanical ventilation or RRT on admission to the
ICU, comorbidities and the inotrope score. We also
adjusted for ICU and hospital-related organizational fac-
tors including type of hospital, ICU specialty, total num-
ber of ICU patients in 2011 and number of staffed ICU
beds. Geographic region and GNI were also considered.
Collinearity between variables was excluded before mod-
elling and the time-dependent covariate method was
used to check the proportional hazard assumption of the
model. The cumulative incidence functions of death ac-
cording to AKIN stage within the first 72 hours of ad-
mission or CRF were plotted and Gray’s test was used to
test cause-specific death differences [20, 21]. To quantify
the association between the direction of the evolution of
the AKI and sepsis, a cumulative link mixed-effects or-
dinal response model with logit link function was fitted.
The random intercept model was used. The longitudinal
ordinal response variable, AKIN stage, was the main
dependent. The explanatory variables were the time
points of AKIN stage assessment (admission/follow-up),
sepsis (yes/no) and their interaction [22, 23]. Two-sided
p < 0.05 was considered statistically significant. Data
were analysed using IBM® SPSS® Statistics software, ver-
sion 23 for Windows (IBM, Armonk, NY, USA) and R
software, version 2.10.1 (CRAN project).
Results
A total of 10 069 patients were included in the ICON
audit [15]; most patients were from ICUs in Europe (54%),
Asia (19%) and the Americas (17%). Because of missing
serum creatinine and urine output data, 9579 patients
(95%) were eligible for the present analyses; 764 patients
developed sepsis during the ICU stay (≥ 2 days after
admission) and were excluded. The 845 patients with
pre-existing CRF were analysed as a separate subgroup.
Of the remaining 7970 patients, 1946 (24%) had sepsis on
admission. A total of 4727 patients met the criteria for
AKI within 72 hours after ICU admission (diagnosis was
based on creatinine criteria alone in 14% of patients, urine
output criteria in 85% and both criteria in 1%, using the
component that led to the worst possible AKIN classifica-
tion in each case). AKI was more frequent (n = 1318
(68%) vs n = 3409 (57%), p < 0.001) and more severe in
patients with sepsis on admission than in those without
(Fig. 1). The demographic and clinical characteristics of
these patients are presented in Tables 1 and 2.
AKI follow-up
By the 7-day follow-up, sepsis patients without AKI
within the first 72 hours of ICU admission were less
likely to have developed AKI compared to the
non-septic population (n = 325 (52%) vs n = 1582 (60%),
p < 0.0001). Sepsis patients admitted with AKIN stage 1
or 2 were more likely to have complete recovery of AKI,
compared to patients without sepsis for the same AKIN
stage (n = 206 (36%) vs n = 522 (26%) for AKIN stage 1
and p < 0.0001; n = 65 (30%) vs n = 130 (21%) for AKIN
stage 2, p = 0.005, respectively). However, sepsis patients
with AKIN stage 3 were less likely to have recovered to
a lower AKIN stage by day 7 than non-septic patients
with AKIN stage 3 (n = 108 (21%) vs n = 258 (32%), p <
0.0001). The random intercept model using time points
of AKI measurements (admission/follow-up), sepsis (yes/
no) and their interaction showed that the estimated par-
ameter for interaction was – 0.62 ± 0.08, p < 0.001, con-
firming that sepsis patients with less severe AKI were
more likely to recover renal function within the first
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week after admission than non-septic patients, whereas
sepsis patients with more severe AKI (AKI stage 3) were
less likely to recover renal function than non-sepsis pa-
tients with AKI stage 3.
Renal replacement therapy and length of stay
The use of RRT was greater in the septic patients than
in the non-septic population (n = 380 (20%) vs n = 326
(5%), p < 0.0001; Additional file 4A). During the first 4
days, haemofiltration was the most frequent form of
RRT in sepsis patients and haemodialysis in non-septic
patients (Additional file 3: Table S2). RRT use was great-
est in patients admitted with AKIN stage 3 in patients
with and without sepsis (Table 3). In patients admitted
with AKIN stage 3, RRT use was more frequent in
patients who remained in stage 3 than in those who
improved (Additional file 4B). In patients with AKIN
stage 3, RRT was more often initiated in upper-middle
and high income-class countries compared to low and
lower-middle income-class countries (Additional file 3:
Table S3). RRT treatment modality for each region and
income class is presented in Additional file 3: Table S4.
ICU and hospital LOS was longer for patients admit-
ted with sepsis compared to patients without sepsis (8
(4–60) vs. 3 (2–6), p < 0.001 and 38 (14–60) vs 11 (6–
32), p < 0.001, respectively) and increased with increas-
ing AKI severity (Table 3). ICU and hospital LOS for
each region and income class is presented in Additional
file 3: Table S5.
Mortality
Crude mortality rates were higher in patients receiving
RRT compared to those without RRT (ICU mortality, sepsis
n = 150 (40%) vs n = 341 (22%) and no sepsis n = 91 (29%)
vs n = 564 (10%); in-hospital mortality, sepsis n = 180
(49%) vs n = 71 (32%) and no sepsis n = 105 (34%)
vs n = 764 (14%), all p < 0.001). Of those receiving
RRT, in-hospital mortality was higher in non-septic
patients receiving haemofiltration compared to haemodi-
alysis, whereas in the septic group there were no differ-
ences between the modalities (Additional file 3: Table S6).
Crude in-hospital mortality rates for patient with and
those without sepsis were 2–3-fold higher in patients
with AKIN stage 3 compared to patients without AKI
and were higher for each AKIN stage compared to no
AKI in patients with sepsis (Table 3). In patients with
AKIN stage 3, in-hospital mortality was comparable for
each income class (Additional file 3: Table S3).
In patients with sepsis, crude in-hospital mortality was
greatest in those admitted with AKI stage 3 and AKI
stage 2 who had not recovered by day 7 (Additional file 5);
in patients without sepsis, this relationship was only
present in patients with AKI stage 3. AKI stage 3 patients
who fully recovered renal function had a 13% (septic pa-
tients) and 20% (non-septic patients) lower in-hospital
mortality compared to those who remained in stage 3 at
day 7. However, in-hospital mortality in these patients was
still twice as high compared to patients recovering from
AKI stages 2 and 1 (Additional file 3). Cumulative survival
curves are shown in Fig. 2. AKI stages 2 and 3 were asso-
ciated with significantly higher hazard ratios of crude ICU
and hospital mortality in septic and non-septic patients
compared to no AKI (Table 4). When adjusted for co-
variates, AKI stage 3 was still associated with ICU
and in-hospital mortality in both patient groups (with
and without sepsis) and AKI stage 2 was associated
with in-hospital mortality in patients without sepsis
(Table 4).
Fig. 1 Change in severity of acute kidney injury (AKI) in septic and non-septic critically ill patients over 7 days. Vertical bar graphs represent AKI
diagnosed at ICU admission in septic patients (left) and non-septic patients (right), according to AKIN categories: No AKI, stage 1, 2 and 3. Horizontal
bar graphs (middle) represent change in AKI stage on day 7 according to AKI admission category. For example, of the 30% (n = 575) of septic patients
with AKI stage 1, 27% (n = 155) remained in the AKI stage 1 group, 36% (n = 206) improved to No AKI, 8% (n = 45) worsened to stage
2 and 29% (n = 169) worsened to stage 3
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Patients with chronic renal failure
Of the 845 patients with a medical history of CRF, 263
(31%) had sepsis on admission. Baseline demographic
and clinical characteristics are presented in Additional
file 3: Tables S7 and S8. Use of RRT and ICU and
in-hospital LOS and mortality are presented in Add-
itional file 3: Table S9. Patients with CRF had lower ICU
and in-hospital mortality rates than those with AKI stage
3 patients (sepsis p = 0.017; non-sepsis: p < 0.001) (Fig. 2).
When adjusted for covariates, these differences disap-
peared in patients with sepsis, but remained in patients
without sepsis (Table 4).
Discussion
The data obtained from this large international multi-
centre audit confirm previously reported prevalences of
AKI and that the condition is more common in patients
with sepsis than in those without [4, 7–9, 24]. Our data
on the changes in severity of AKI mirror those of the
FINAKKI study, in which 86% of critically ill patients
admitted with AKIN stage 3 remained in this most
severe stage [4]. Our results also corroborate those from
a study by Hoste et al. [7], in which more than half of
the AKI-Risk (similar to AKIN stage 1) patients and
one-third of the AKI-Injury (similar to AKIN stage 2)
patients deteriorated during the ICU stay. However,
neither of these studies differentiated between patients
with and without sepsis. Moreover, although it is well
known that increasing severity of AKI is associated with
a higher mortality [7], we also show that transition to a
lower AKIN stage within 7 days is associated with an
improvement in survival. Nevertheless, once AKIN stage
3 is reached, hospital mortality remains high, even if
there is apparent full renal recovery within 7 days after
ICU admission.
AKI in patients with and without sepsis
We observed that septic patients with less severe AKI
were more likely to recover renal function during the
first week after admission than non-septic patients with
Table 3 Clinical outcomes
Sepsis (n = 1946) No sepsis (n = 6024)
No AKI
(n = 628)
Stage 1
(n = 575)
Stage 2
(n = 219)
Stage 3
(n = 524)
No AKI
(n = 2615)
Stage 1
(n = 1976)
Stage 2
(n = 627)
Stage 3
(n = 806)
ICU LOS (days), median (IQR) 7 (2–22)b 7 (3–29)b 8 (4–54)ab 19 (6–60)ab 3 (1–5) 3 (2–5) 2 (1–6)a 4 (2–60)a
Hospital LOS (days), median (IQR) 25 (12–60)b 28 (13–60)b 49 (14–60)ab 60 (22–60)ab 10 (6–22) 10 (6–24) 11 (6–35)a 20 (7–60)a
RRT, n (%) 25 (4.0)b 33 (5.7)b 15 (6.8)b 307 (58.6)ab 27 (1.0) 22 (1.1) 10 (1.6) 267 (33.1)a
ICU mortality, n (%) 108 (17.6)b 117 (20.6)ab 50 (23.5)ab 216 (41.5)ab 213 (8.4) 138 (7.2) 76 (12.4)a 228 (29.2)a
Hospital mortality, n (%) 154 (25.9)b 162 (29.3)ab 74 (35.6)ab 261 (51.7)ab 286 (11.8) 219 (11.9) 102 (17.4)a 262 (34.6)a
AKI acute kidney injury, ICU intensive care unit, LOS length of stay, IQR interquartile range, RRT renal replacement therapy, n number of patients
aSignificant at 5% level vs No AKI in the same group (sepsis or no sepsis)
bSignificant at 5% level vs no sepsis patients with the same AKIN stage
Fig. 2 Cumulative incidence functions of death in critically ill patients with (left) and without (right) sepsis according to acute kidney injury (AKI)
stage on admission and presence of comorbid chronic renal failure (CRF)
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the same initial degree of AKI, whereas septic patients
admitted with AKIN stage 3 were less likely to recover
to a lower AKIN stage. Importantly, sepsis and
non-sepsis groups are not necessarily similar at baseline,
as patients with sepsis are more likely to have early,
evolving AKI, and so changes in illness trajectory may
reflect a temporal bias, rather than the influence of the
underlying disease. Also, if the bar is set at the creatinine
level at admission, it may be easier for patients who have
a lower creatinine level pre admission to get back to this
level. Clearly, there also are differences in the distinct
pathogenesis of septic versus non-septic AKI. Although
a variety of mechanisms are involved in the development
of AKI [25], AKI in patients with sepsis may predomin-
antly be the consequence of the dysregulated inflamma-
tory response to an infection, resulting in renal
inflammation, microcirculatory dysfunction and cell bio-
energetic adaptive responses [13]. Clearing underlying
infection may be more likely to help AKI resolution in
milder cases of sepsis-associated AKI than in more se-
vere stages. Conversely, non-septic AKI may be related
more to extensive damage to the micro-architecture of
the kidney, requiring prolonged periods for repair and
renal recovery. In support of this suggestion, autopsy
investigations did not reveal widespread tubular damage
or cell death in septic AKI [26].
Influence of RRT and transition to another AKIN stage
In this study, RRT was mostly started within the first 2
days after ICU admission and predominantly in patients
admitted with AKIN stage 3 who did not recover during
the first week after admission. It is currently unclear
whether or not early initiation of RRT may improve
patient outcome [27, 28] despite two large clinical trials
[29, 30] and further study, such as the ongoing
STARRT-AKI trial (ClinicalTrials.gov NCT02568722), is
necessary to elucidate the effects of RRT timing on out-
comes and to guide clinical decisions related to the initi-
ation of RRT.
Although in-hospital mortality was lower in patients
with renal recovery, septic and non-septic AKIN stage 3
patients who had recovered full renal function by day 7
still had a 2-fold higher in-hospital mortality rate than
patients recovering from AKI stage 2 or 1 or patients
without AKI. In addition, our data confirm that mortal-
ity is higher in patients who receive RRT compared to
those who do not [31]. Our hypothesis-generating data
could encourage a novel approach to risk stratification
in AKI for current therapy, future investigations and
clinical therapeutic trials. For example, in the absence of
life-threatening complications, it may be prudent to
delay RRT, as a large number of patients, especially in
the lower AKIN stages, recovered full renal function. In-
deed, use of RRT may delay recovery of renal function
[32]. While resuscitation strategies appear not to influ-
ence the development of AKI in patients with septic
shock [33], secondary prevention, by mitigating further
toxic and haemodynamic renal insults, may represent an
important therapeutic opportunity in this population.
Also, models of ICU mortality and prognostic scores
could likely be refined by considering the dynamic
changes in renal function over time.
Limitations of this study
Our study has several limitations. Firstly, we lack infor-
mation about secondary or post-day 7 renal insults that
may have occurred as a result of hypotension, adverse
drug reactions or inappropriate blood pressure targets.
Table 4 Hazard ratios for mortality
Sepsis No sepsis
Crude HR (95% CI) Covariate-adjusted HR (95% CI) Crude HR (95% CI) Covariate-adjusted HR (95% CI)
ICU mortality
Stage 1 1.16 (0.91–1.49)c 1.03 (0.80–1.33)c 0.84 (0.68–1.04)c 0.83 (0.67–1.02)c
Stage 2 1.39 (1.01–1.92)a 1.30 (0.94–1.80) 1.49 (1.15–1.95)ac 1.21 (0.94–1.57)
Stage 3 2.77 (2.22–3.46)abc 1.90 (1.48–2.43)a 4.06 (3.36–4.91)ac 2.25 (1.83–2.76)ac
CRF 1.67 (1.26–2.22)a 1.54 (1.13–2.10)a 2.21 (1.74–2.81)a 1.38 (1.07–1.77)a
Hospital mortality
Stage 1 1.12 (0.91–1.39)c 0.99 (0.79–1.23)c 0.98 (0.82–1.17)c 0.94 (0.79–1.12)c
Stage 2 1.46 (1.12–1.89)a 1.27 (0.96–1.68) 1.51 (1.20–1.90)ac 1.26 (1.01–1.58)a
Stage 3 2.47 (2.04–2.99)abc 1.74 (1.41–2.16)a 3.61 (3.03–4.29)ac 2.26 (1.87–2.72)ac
CRF 1.76 (1.39–2.22)a 1.54 (1.18–2.01)a 2.28 (1.85–2.80)a 1.44 (1.15–1.81)a
No AKI is the reference category. Hazard ratios were estimated by competing risk regression models
HR hazard ratio, CI confidence interval, ICU intensive care unit, CRF chronic renal failure
aSignificant at 5% level vs No AKI in the same group (sepsis or no sepsis)
bSignificant at 5% level vs non-sepsis patients with the same AKIN classification
cSignificant at 5% level vs CRF in the same group (sepsis or no sepsis)
Peters et al. Critical Care  (2018) 22:188 Page 9 of 11
These factors can play an important role in the deterior-
ation or improvement of AKI. Secondly, renal function
was assessed using the AKIN criteria, a widely accepted
and validated classification system for AKI in the critic-
ally ill [17], which we adjusted because urine output was
only available per 24-hour period. As a consequence of
using AKIN categories and not absolute creatinine
values, smaller changes could be missed. Importantly,
patients admitted to the ICU with ongoing AKI may be
missed using these criteria and/or the severity of AKI
was not correctly identified because pre-ICU admission
reference creatinine values were not available, as is fre-
quently the case in clinical ICU practice. This may limit
the determination of the clinical consequences of deteri-
oration or resolution of AKI, and may hamper compari-
son between sepsis and non-sepsis patients. Thirdly, we
have no data enabling analysis of longer term conse-
quences of AKI and progression to chronic kidney
disease or AKI relapse in patients who had recovered
normal renal function by day 7. These long-term conse-
quences, stratified by evolution of AKI, represent an im-
portant area for future investigations. Fourthly, although
the worldwide inclusion of patients provides valuable
insight into the global burden of AKI, the causes of AKI
vary by country and economic status [34]. Also, re-
sources may differ in various regions around the world,
which could influence the clinical outcome of AKI
patients. However, we showed that although the use of
dialysis in AKIN stage 3 patients was higher in
upper-middle and high-income countries compared to
low and lower-middle-income countries, in-hospital
mortality rates were comparable across income classes
in these patients. Finally, some centres included a lim-
ited number of patients, possibly leading to sampling
bias, and the voluntary participation of ICUs may have
resulted in compliance bias. Nevertheless, this is a pro-
spective study in which a large number of patients was
included from all over the world with daily assessment
of renal function, enabling a useful comparison of the
prevalence and evolution of AKI and its consequences
among patients with and without sepsis.
Conclusion
AKI is more frequent, more severe, less likely to resolve
once AKIN stage 3 has been reached and associated with
higher mortality rates in patients with sepsis than in
those without. Differences in the phase of AKI develop-
ment and aetiology of AKI likely account for these
observations in sepsis and non-sepsis patients. Deterior-
ation to a more severe stage of AKI negatively influences
clinical outcome, while improvement is associated with
increased survival. These results emphasize the severity
of the disease, which represents a tremendous burden
for both patients and society.
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